KEYNOTE-866:围手术期帕博利珠单抗联合新辅助化疗治疗顺铂可耐受肌层浸润性膀胱癌
KEYNOTE-866 是一项双盲 III 期研究,907 例顺铂可耐受的肌层浸润性膀胱癌患者随机接受围手术期帕博利珠单抗或安慰剂联合新辅助顺铂+吉西他滨及根治性膀胱切除术。中位随访 60.9 个月,两组 60 个月无事件生存率分别为 63.5% 与 61.9%(HR 0.88,95%CI 0.71-1.10,单侧 P=0.1366),未达统计学显著差异;病理完全缓解率分别为 44.4% 与 35.8%,总生存无差异。
要点
- 围手术期帕博利珠单抗联合新辅助化疗未显著改善顺铂可耐受 MIBC 的无事件生存。
- 帕博利珠单抗组病理完全缓解率 44.4%,安慰剂组 35.8%,估计差异 8.9%。
- 两组中位总生存均未达到,HR 1.00(95%CI 0.79-1.27)。
核心结论
- 在顺铂可耐受的肌层浸润性膀胱癌患者中,围手术期帕博利珠单抗联合新辅助化疗及根治性膀胱切除术未带来统计学显著的无事件生存获益。
- 帕博利珠单抗的安全性可控,与既往报告一致。
研究设计与样本
- 双盲、III 期 KEYNOTE-866 研究,纳入 907 例顺铂可耐受的肌层浸润性膀胱癌患者,随机 1:1 分配至帕博利珠单抗组(n=453)或安慰剂组(n=454)。
- 入组条件为年龄≥18 岁、中心评估临床分期 T2-T4aN0M0 或 T1-T4aN1M0、尿路上皮组织学≥50%,且适合顺铂化疗和膀胱切除术。
- 治疗方案:新辅助帕博利珠单抗或安慰剂联合化疗每 3 周 4 周期,随后根治性膀胱切除加盆腔淋巴结清扫,再辅助帕博利珠单抗或安慰剂每 3 周 13 周期。
- 主要终点为研究者评估的无事件生存期;关键次要终点为盲法独立中心病理评估的病理完全缓解率和总生存期;安全性为次要终点。
主要发现
- 中位随访 60.9 个月(范围 40.7-78.7),60 个月时帕博利珠单抗组估计无事件生存率为 63.5%,安慰剂组为 61.9%(HR 0.88,95%CI 0.71-1.10,单侧 P=0.1366)。
- 病理完全缓解率帕博利珠单抗组为 44.4%,安慰剂组为 35.8%(估计差异 8.9%,95%CI 2.5-15.1)。
- 两组中位总生存均未达到(HR 1.00,95%CI 0.79-1.27)。
- 治疗中出现的不良事件发生率帕博利珠单抗组为 99.8%(≥3 级 80.2%),安慰剂组为 98.7%(≥3 级 75.1%)。
临床怎么用
- 对于顺铂可耐受的肌层浸润性膀胱癌,围手术期帕博利珠单抗联合新辅助化疗及膀胱切除术未显著改善无事件生存,不应作为该人群的标准治疗推荐。
- 帕博利珠单抗在该方案下的安全性可控,但治疗中出现的不良事件及≥3 级不良事件发生率较高,需密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative PD-(L)1 inhibitors, either combined with cisplatin-based chemotherapy or enfortumab vedotin, have improved outcomes in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin eligible. The double-blind, phase III KEYNOTE-866 study evaluated perioperative (neoadjuvant and adjuvant) pembrolizumab versus placebo added to neoadjuvant cisplatin plus gemcitabine (chemotherapy) and radical cystectomy with pelvic lymph node dissection (cystectomy) in MIBC. PATIENTS AND METHODS: Eligible participants were aged ≥18 years, had centrally assessed clinical stage T2-T4aN0M0 or T1-T4aN1M0 MIBC with ≥50% urothelial histology, and were eligible for cisplatin-based chemotherapy and cystectomy. Participants were randomly assigned (1:1) to neoadjuvant pembrolizumab or placebo plus chemotherapy every 3 weeks for 4 cycles, followed by cystectomy, and adjuvant pembrolizumab or placebo every 3 weeks for 13 cycles (pembrolizumab or placebo group, respectively). Primary end point was event-free survival (EFS) by investigator assessment. Pathological complete response (pCR) rate by blinded independent central pathological review and overall survival (OS) were key secondary end points. Safety was a secondary end point. RESULTS: Overall, 907 participants were randomly assigned (pembrolizumab, n = 453; placebo, n = 454). Median follow-up was 60.9 months (range, 40.7-78.7). At 60 months, the estimated EFS rate was 63.5% with pembrolizumab versus 61.9% with placebo (hazard ratio 0.88; 95% CI 0.71-1.10; one-sided P = 0.1366). The pCR rate was 44.4% versus 35.8% (estimated difference 8.9%; 95% CI 2.5-15.1); median OS was not reached in both groups (hazard ratio 1.00; 95% CI 0.79-1.27). Treatment-emergent adverse events occurred in 99.8% of participants in the pembrolizumab group (grade ≥3 in 80.2%) and 98.7% in the placebo group (grade ≥3 in 75.1%). CONCLUSIONS: The addition of perioperative pembrolizumab to neoadjuvant chemotherapy and cystectomy did not confer a statistically significant EFS benefit in participants with MIBC who are cisplatin eligible. The safety profile of pembrolizumab was manageable and consistent with prior reports.
引用
- Bedke J, Arkosy P, Nishiyama H, et al. Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study. Ann Oncol. 2026. PMID: 42918422. doi:10.1016/j.annonc.2026.10.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。